Functional Dyspepsia
Conditions
Brief summary
The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are: * Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation? * Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia. Participants will: * Take one capsule of the probiotic or placebo once daily before meals for 60 days * Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months * Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months * Attend scheduled study visits for checkups and assessments
Interventions
OTHERLactobacillus
5 billion CFU of lactobacilus ans streptococci once daily for 60 days
OTHERMaltodextrin (Placebo)
Placebo capsules will be given one a day for 60 days
Sponsors
Nordic Biotic Sp. z o.o.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-65 years 2. Diagnosis of Functional Dyspepsia based on Rome IV criteria, with symptoms present for at least 3 months, and symptom onset at least 6 months before diagnosis, including: * Postprandial fullness * Early satiation * Epigastric pain or burning * (with no evidence of structural disease explaining symptoms) 3. Moderate to severe symptom severity at baseline, as defined by a validated scale (e.g., NDI or global symptom score) 4. Normal upper GI endoscopy within the last 12 months (or at screening), excluding structural disease (e.g., peptic ulcer, malignancy) 5. Negative for H. pylori (either previously treated successfully or tested negative within study screening) 6. Ability and willingness to provide informed consent and comply with study procedures 7. Stable medication use, if any, for at least 4 weeks before screening (e.g., PPIs, antidepressants, laxatives)
Exclusion criteria
1. Evidence of structural GI disease (e.g., peptic ulcer, gastric cancer, celiac disease) on recent or screening endoscopy 2. History of gastrointestinal surgery affecting stomach or small intestine (except appendectomy or cholecystectomy) 3. Positive test for H. pylori during screening (or untreated known infection) 4. Current or recent use (within 4 weeks) of antibiotics, pre-, pro- or postbiotics, unless part of study protocol 5. Use of medications affecting GI motility (e.g., prokinetics, opioids, anticholinergics) within 2-4 weeks before enrollment 6. Overlap with other functional GI disorders (except IBS) if they are the dominant complaint, unless your protocol allows overlap 7. Clinically significant psychiatric illness (e.g., major depression, schizophrenia) that may interfere with symptom reporting or adherence 8. Severe systemic or metabolic disease (e.g., uncontrolled diabetes, renal or hepatic failure) 9. Pregnancy or lactation, or intention to become pregnant during the study period 10. Participation in another clinical trial within the past 3 months 11. Known allergy or intolerance to study product components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Gastrointestinal Symptom Rating Scale | 30 and 60 days |
Contacts
Primary ContactSergiy Gerasymov, MD, PhD
Backup ContactMałgorzata Tyx-Dąbkowska
Outcome results
None listed